DEB or DES for the treatment of calcified nodules after intravascular lithotripsy: the DEBSCAN-IVL trial design.
Alfonso Jurado-Román, Mattia Basile, José M Montero-Cabezas...
https://pubmed.ncbi.nlm.nih.gov/42745725/Actively Recruiting
Led by Fundación EPIC · Updated on 2026-09-30
128
Participants Needed
15
Research Sites
N/A
Total Duration
Researchers are evaluating treatment options for patients with coronary artery disease caused by calcified nodules. This international, multicenter, open-label randomized trial compares two approaches after using intravascular lithotripsy to modify the plaque drug eluting balloons DEB and drug eluting stents DES. The study aims to assess the safety and effectiveness of these treatments and to determine if DEB is at least as good or possibly better than DES in this setting. Participants undergo a percutaneous coronary intervention PCI involving intravascular lithotripsy to break up the calcified plaques. They are then randomly assigned to receive either a drug eluting balloon or a drug eluting stent to treat the lesion. This leave-nothing-behind strategy is studied for its potential to reduce risks related to stent placement. The trial follows patients for outcomes up to 24 months, with key measurements at 9 and 12 months. During the study, participants receive imaging to confirm the calcified nodule lesion and have follow-up angiographic assessments. Researchers monitor outcomes including late lumen loss and net lumen gain at 9 months, as well as safety events such as vessel dissection, perforation, thrombosis, and major adverse cardiac events up to 24 months. The trial also tracks additional measures like minimal lumen diameter and target lesion revascularization. Participation lasts through treatment and extended follow-up to evaluate both effectiveness and safety.
CONDITIONS
DEBSCAN-IVL. Drug Eluting Balloon or Drug Eluting Stent to Treat CAlcified Nodules After IntraVascular Lithotripsy.
F
FUNDACION EPIC
A
ALFONSO JURADO ROMAN, MD,PhD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Fundación EPIC
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Single procedure with follow-up
Participants undergo percutaneous coronary intervention with intravascular lithotripsy followed by random assignment to receive either a drug eluting balloon or a drug eluting stent to treat the calcified nodule.
Follow-up visits at scheduled intervals up to 24 months
Duration - Up to 24 months
Participants are monitored for treatment effectiveness and safety through imaging and clinical assessments up to 24 months after the procedure.
Regular follow-up visits including angiographic assessments at 9 and 12 months
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Alfonso Jurado-Román, Mattia Basile, José M Montero-Cabezas...
https://pubmed.ncbi.nlm.nih.gov/42745725/Takao Sato, Mitsuaki Matsumura, Kei Yamamoto...
https://pubmed.ncbi.nlm.nih.gov/37164599/Ziad A Ali, Holger Nef, Javier Escaned...
https://pubmed.ncbi.nlm.nih.gov/31553205/Yoshihiro Iwasaki, Jumpei Koike, Toshinori Ko...
https://pubmed.ncbi.nlm.nih.gov/32857188/Toru Morofuji, Shoichi Kuramitsu, Tomohiro Shinozaki...
https://pubmed.ncbi.nlm.nih.gov/32259392/Hee Hwa Ho, Jin Hyun Lee, Deanna Zhi Lin Khoo...
https://pubmed.ncbi.nlm.nih.gov/34527034/Tetsumin Lee, Gary S Mintz, Mitsuaki Matsumura...
https://pubmed.ncbi.nlm.nih.gov/28797410/Fundación EPIC
Lead Sponsor